Please assess the completion status of the following clinical trial:

Trial Title: Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smoke 3-30 cigarettes/day~* Desire to quit smoking as indicated on a smoking stages ladder~* Consume \>14 (men) or \>7 (women) standard alcohol drinks per week (e.g., 1 drink = 12 oz beer, 5 oz wine, 1.5 oz liquor)~* Ability to understand, read, and write in English, at least 8th grade education~* Willing and able to sign an informed consent~* Stable residence and contact information.~Exclusion Criteria:~* Hepatic panel indices \> 2 SD~* History of seizures or DTs during alcohol withdrawal~* Unstable medical (e.g., hepatitis, cirrhosis, seizure disorder, recent major cardiovascular event, etc.) or psychiatric disorder (e.g., active hallucinations, severe depression, obsessional thinking, self-injury risking significant blood loss, etc.) deemed by the study physician to be at significant risk for adverse interactions with study medications or measures.~* History of adverse reactions to varenicline (VAR) or nicotine patch~* Current suicidal ideation (past 6 months) and/or history of major suicide attempts.~* For women of child-bearing potential: currently pregnant, lactating, current plans to become pregnant in next three months, or unable to agree to adequate birth control during study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Augmented Treatment (Type: EXPERIMENTAL): Participants receive 12 weeks of Chantix along with standard smoking cessation treatment of nicotine patches and behavioral counseling visits.~* Chantix (Varenicline) and NicodermCQ (Nicotine Patches): Administered according to package insert directions~* Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings.
- Standard Treatment w/ placebo (Type: ACTIVE_COMPARATOR): Participants receive 12 weeks of standard smoking cessation treatment of nicotine patches and behavioral counseling visits in addition to placebo pills identical in appearance to varenicline~* Placebo pills (identical to varenicline)~* NicodermCQ (Nicotine Patches): Administered according to package insert directions~* Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings.

Based on this trial design, predict the completion outcome and termination type (if applicable).